Table 2 Applications of various nanoplatforms of SNA as carriers in delivery systems
From: Recent advances in gene delivery nanoplatforms based on spherical nucleic acids
Nano-platforms | Oligonucleotide shell | Disease model | Cell line tested | Assayed genes | Assayed conditions | Refs |
|---|---|---|---|---|---|---|
Alkyl-PEI2k-Cdot | siRNA /plasmid DNA (pDNA) | Breast cancer | 4T1 | Luciferase gene | Invitro/in vivo | [186] |
Gal-PEI-SPIO | siRNA | Hepatocellular carcinoma | Hepa1-6 (Hepatoma) | c-Met | Invitro/ in vivo | [1] |
Lipidoid-Coated Iron Oxide | DNA and siRNA | – | HeLa cells | Luciferase | Invitro | [90] |
LNP-Luc-SNA | siRNA | – | RAW 264.7-Lucia ISG, U87-MG-Luc2 | Luciferase | Invitro/ in vivo | [58] |
Adr-siRap2b-Au-SNA | siRNA | Colorectal cancer | HCT116, MCF-7 | Rap2b | Invitro/ in vivo | [3] |
siGM3S-Au-SNA | siRNA | Diabetic skin wound | Keratinocytes | Ganglioside-monosialic acid 3, IGF1R, EGFR | Invitro/ in vivo | [144] |
siBcl2L12-Au-SNA | siRNA | Glioblastoma | U87MG, LNZ308, and LNZ235 | Bcl2L12, caspase-3, caspase-7 | Invitro/ in vivo | [145] |
siGli-SNA | siRNA | Glioblastoma | U87MG, SF767, GIC-20 | Gli1, Smo, CyclinD1, c-Myc, Bcl2, and ABCG2 | Invitro | [146] |
siHIF1α- Bcl-2(ASO)- PNA- photolabile SNA | siRNA/ASO | Cervical cancer | HeLa | HIF-1α, Bcl-2 | Invitro/ in vivo | [147] |
siGFP | siRNA | glioma | U87-MG | GFP | Invitro | [138] |
siTNFa-Au-SNA | siRNA | Inflammatory diseases | Murine macrophage RAW264.7 | TNF-α | Invitro | [148] |
siGFP/siGAPDH-Au- SNA(s) | siRNA | – | Hela, C166 GFP-expressing | GFP, GAPDH | Invitro | [149] |
hairpin-like siRNA-SNA | siRNA | Ovarian cancer | SK-OV-3 | HER2, Luc, VEGF | Invitro | [150] |
siAR- Au-SNA | siRNA | Prostate cancer | Lymph node carcinoma of the prostate (LNCaP) | Androgen receptor | Invitro/ in vivo | [151] |
siEGFR- Au-SNA | siRNA | Skin-related diseases | Human keratinocyte | EGFR | Invitro/ in vivo | [192] |
Carbon-siPlk1-SNA | siRNA | Breast cancer, melanoma cancer | MCF-7, A375 | Polo-like kinase-1 | Invitro/ in vivo | [153] |
siIKKβ-Au-SNA | siRNA | Islet transplantation | Islets cells | IκB kinase (IKK) subunit (IKKβ) of NF-κB | Invitro/ in vivo | [154] |
GL-3 siRNA- DNA nanoclew (DC) -SNA | siRNA | – | HeLa-Luc | Luciferase | Invitro | [1] |
miR-182-Au-SNA | microRNA | Glioblastoma | Gliomas | Caspase, p53 inhibitor, Bcl2L12, c-Met, and HIF2A | Invitro/ in vivo | [160] |
miR-182-Au-SNA | microRNA | Glioblastoma | LN229, LNZ308, U87MG | Bcl2L12, caspase-3, caspase-7, Ki67 | Invitro/ in vivo | [160] |
miR-34a-Reporter-Fuel-SNA | MicroRNA | Breast cancer | MCF-7 | miR-34a, survivin | Invitro | [161] |
Anti-miR21-nanoflare-Au-SNA | MicroRNA | Prostate cancer | PC-3 | miR-21 | Invitro | [162] |
Anti-miRNA-92b-ApoE/ RVG- Liposomal SNA | MicroRNA | Glioblastoma | U87 GBM | miRNA-92b | Invitro/ in vivo | [163] |
Anti-miR21-polyA-Au-SNA | MicroRNA | Breast cancer | HEK293T, 293T, MCF-7 | miR-21, TPM, EGFP | Invitro/ in vivo | [164] |
Anti-miR99b-Au-SNA | MicroRNA | Sepsis | RAW264.7 | miR-99b, MFGE8 | Invitro/ in vivo | [166] |
Anti-miR-34a -Au-photoresponsive SNA | MicroRNA | Breast cancer | MCF-7 | miR-34a, Notch, LMTK3, survivin | Invitro | [167] |
miR-145-Au-SNA | MicroRNA | Prostate cancer, breast cancer | MCF-7, PC3 | miR-145 | Invitro | [168] |
miR-130b-Au-SNA | MicroRNA | Multiple myeloma | MM.1 S | GR-α, miR-130b | In vitro | [169] |
TGF-β1- Au /Liposomal-SNA | ASO | Abnormal scars | HSF, KF | TGF-β1 | In vitro/ in vivo | [172] |
TNF-α -Liposomal-SNA | ASO | Psoriasis | Keratinocytes | TNF-α | In vitro /ex vivo/ in vivo | [174] |
IL17RA-Liposomal-SNA | ASO | Psoriasis | Keratinocytes | Il17RA, Tnf-α, S100a7a, Defb4, Il17c, Il6, Pi3, and Krt16, Krt10, Lor | In vitro /ex vivo/ in vivo | [175] |
MC1R- PR10- micellar-SNA | ASO | Hyperpigmentation | B16F10 | TYR, MC1R | In vitro/ in vivo | [176] |
TLR-TAK 242-Liposomal-SNA | ASO | Immune disorders | HEK293 | TLR4, TLR9, NF-κB, TLR | In vitro | [178] |
Malat1- PS-LSNAs | ASO | Adenocarcinoma | A549 | Malat1 (lncRNA), IFIT2 | In vitro | [109] |
APOB -FANA-SNA Survivin- FANA-SNA Luciferase- FANA-SNA | ASO | Breast cancer, cervical cancer, liver cancer | HeLa, HepG2, MCF-7, MDA-453 | APOB, Survivin, Luciferase | In vitro | [181] |
BCL2- AIE PS-SNA | ASO | Breast cancer, cervical cancer | HeLa, MCF-2 | BCL2 | In vitro/ in vivo | [49] |
hollow silica-based SNA | ASO | – | Mouse endothelial cells | eGFP | In vitro | [81] |
Fe3O4@SiO2/PAH/pDNA | Plasmid DNA | Cervical cancer | HeLa cells | – | In vitro | [185] |
Fe3O4/plasmid DNA | Plasmid DNA | – | PK-15 | Genes encoding a green (DNAGFP) or red (DNADsRed) fluorescen | In vitro | [193] |
Dual-Responsive γ-Fe2O3@PDMAEMA | Plasmid DNA (Plasmid pH2B-EGFP) | – | E. coli DH5 alpha strain | EGFP | In vitro | [93] |
MGMT- ribozyme- Au − SNA | Ribozyme | Glioblastoma | T98G | MGMT | In vitro | [36] |
Immune-stimulatory- CpG-rich- LSNAs | CpG-rich | Triple Negative Breast cancer (TNBC) | MDSC, T-cell lymphocyte | – | Ex vivo-in vivo | [189] |
Immune-stimulatory-liposomal- lys-SNAs | CpG-rich | Triple Negative Breast cancer (TNBC) | CD8 + T, MDSC, dendritic cell | – | In vivo | [190] |
Au/liposomal- TLR9 (IS/IR)- SNAs | CpG-rich-TLR9 agonist/ antagonist | Fibrosis score in nonalcoholic steatohepatitis (NASH) | RAW 264.7 | – | In vivo | [191] |